Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 120 entries
Sorted by: Best Match Show Resources per page
Non-steroidal treatment of cardiac sarcoidosis: A systematic review.

International journal of cardiology. Heart & vasculature

Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, Young BD, Miller EJ.
PMID: 33997256
Int J Cardiol Heart Vasc. 2021 Apr 29;34:100782. doi: 10.1016/j.ijcha.2021.100782. eCollection 2021 Jun.

The treatment of active cardiac sarcoidosis (CS) usually involves immunosuppressive therapy, with the goal of preventing inflammation-induced scar formation. In most cases, steroids remain the first-line treatment for CS. However, given the side effect profile of their long-term use,...

Cite
Gallegos C, Oikonomou EK, Grimshaw A, et al. Non-steroidal treatment of cardiac sarcoidosis: A systematic review. Int J Cardiol Heart Vasc. 2021;34:100782doi: 10.1016/j.ijcha.2021.100782.
Gallegos, C., Oikonomou, E. K., Grimshaw, A., Gulati, M., Young, B. D., & Miller, E. J. (2021). Non-steroidal treatment of cardiac sarcoidosis: A systematic review. International journal of cardiology. Heart & vasculature, 34100782. https://doi.org/10.1016/j.ijcha.2021.100782
Gallegos, Cesia, et al. "Non-steroidal treatment of cardiac sarcoidosis: A systematic review." International journal of cardiology. Heart & vasculature vol. 34 (2021): 100782. doi: https://doi.org/10.1016/j.ijcha.2021.100782
Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, Young BD, Miller EJ. Non-steroidal treatment of cardiac sarcoidosis: A systematic review. Int J Cardiol Heart Vasc. 2021 Apr 29;34:100782. doi: 10.1016/j.ijcha.2021.100782. eCollection 2021 Jun. PMID: 33997256; PMCID: PMC8105294.
Copy Download .nbib Format: NLM
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision.

RMD open

Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J.
PMID: 34880127
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987.

OBJECTIVES: To compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on rheumatology care provision.METHODS: Through nationwide...

Cite
Bower H, Frisell T, di Giuseppe D, et al. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021;7(3)doi: 10.1136/rmdopen-2021-001987.
Bower, H., Frisell, T., di Giuseppe, D., Delcoigne, B., Ahlenius, G. M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad-d'Elia, H., Kastbom, A., Klareskog, L., Lindqvist, E., Lindström, U., Turesson, C., Sjowall, C., Askling, J. (2021). Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD open, 7(3), . https://doi.org/10.1136/rmdopen-2021-001987
Bower, Hannah, et al. "Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision." RMD open vol. 7,3 (2021). doi: https://doi.org/10.1136/rmdopen-2021-001987
Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjowall C, Askling J. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001987. PMID: 34880127; PMCID: PMC8655349.
Copy Download .nbib Format: NLM
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome.

Lupus science & medicine

Bermas B, Costedoat-Chalumeau N.
PMID: 34996859
Lupus Sci Med. 2022 Jan;9(1). doi: 10.1136/lupus-2021-000630.

No abstract available.

Cite
Bermas B, Costedoat-Chalumeau N. Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome. Lupus Sci Med. 2022;9(1)doi: 10.1136/lupus-2021-000630.
Bermas, B., & Costedoat-Chalumeau, N. (2022). Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome. Lupus science & medicine, 9(1), . https://doi.org/10.1136/lupus-2021-000630
Bermas, Bonnie, and Costedoat-Chalumeau, Nathalie. "Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome." Lupus science & medicine vol. 9,1 (2022). doi: https://doi.org/10.1136/lupus-2021-000630
Bermas B, Costedoat-Chalumeau N. Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome. Lupus Sci Med. 2022 Jan;9(1). doi: 10.1136/lupus-2021-000630. PMID: 34996859.
Copy Download .nbib Format: NLM
Optimal dose of etanercept in the treatment of rheumatoid arthritis.

Open access rheumatology : research and reviews

Curtis EM, Marks JL.
PMID: 27790032
Open Access Rheumatol. 2014 Mar 24;6:27-38. doi: 10.2147/OARRR.S41409. eCollection 2014.

Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy in the management of rheumatoid arthritis (RA). As experience has grown, a number of different treatment strategies have...

Cite
Curtis EM, Marks JL. Optimal dose of etanercept in the treatment of rheumatoid arthritis. Open Access Rheumatol. 2014;6:27-38doi: 10.2147/OARRR.S41409.
Curtis, E. M., & Marks, J. L. (2014). Optimal dose of etanercept in the treatment of rheumatoid arthritis. Open access rheumatology : research and reviews, 627-38. https://doi.org/10.2147/OARRR.S41409
Curtis, Elizabeth Mary, and Marks, Jonathan Lewis. "Optimal dose of etanercept in the treatment of rheumatoid arthritis." Open access rheumatology : research and reviews vol. 6 (2014): 27-38. doi: https://doi.org/10.2147/OARRR.S41409
Curtis EM, Marks JL. Optimal dose of etanercept in the treatment of rheumatoid arthritis. Open Access Rheumatol. 2014 Mar 24;6:27-38. doi: 10.2147/OARRR.S41409. eCollection 2014. PMID: 27790032; PMCID: PMC5045112.
Copy Download .nbib Format: NLM
Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.

Annals of the rheumatic diseases

Piantoni S, Andreoli L, Colombo E, Mendeni M, Ghirardelli ML, Brucato A, Imazio M, Furloni R, Franceschini F, Airó P, Scarsi M.
PMID: 33504480
Ann Rheum Dis. 2021 Jan 27; doi: 10.1136/annrheumdis-2020-219787. Epub 2021 Jan 27.

No abstract available.

Cite
Piantoni S, Andreoli L, Colombo E, et al. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219787.
Piantoni, S., Andreoli, L., Colombo, E., Mendeni, M., Ghirardelli, M. L., Brucato, A., Imazio, M., Furloni, R., Franceschini, F., Airó, P., & Scarsi, M. (2021). Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219787
Piantoni, Silvia, et al. "Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219787
Piantoni S, Andreoli L, Colombo E, Mendeni M, Ghirardelli ML, Brucato A, Imazio M, Furloni R, Franceschini F, Airó P, Scarsi M. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada. Ann Rheum Dis. 2021 Jan 27; doi: 10.1136/annrheumdis-2020-219787. Epub 2021 Jan 27. PMID: 33504480.
Copy Download .nbib Format: NLM
Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series.

Annals of the rheumatic diseases

Kvacskay P, Merkt W, Günther J, Blank N, Lorenz HM.
PMID: 35027400
Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221756. Epub 2022 Jan 13.

No abstract available.

Cite
Kvacskay P, Merkt W, Günther J, et al. Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Ann Rheum Dis. 2022;doi: 10.1136/annrheumdis-2021-221756.
Kvacskay, P., Merkt, W., Günther, J., Blank, N., & Lorenz, H. M. (2022). Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221756
Kvacskay, Peter, et al. "Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series." Annals of the rheumatic diseases vol. (2022). doi: https://doi.org/10.1136/annrheumdis-2021-221756
Kvacskay P, Merkt W, Günther J, Blank N, Lorenz HM. Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221756. Epub 2022 Jan 13. PMID: 35027400.
Copy Download .nbib Format: NLM
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.

Annals of the rheumatic diseases

Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ.
PMID: 35027405
Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221915. Epub 2022 Jan 13.

OBJECTIVES: Recent results from 'ORAL Surveillance' trial have raised concerns regarding the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA). We further examined this safety concern in the real-world setting.METHODS: We created two cohorts of patients with...

Cite
Khosrow-Khavar F, Kim SC, Lee H, et al. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;doi: 10.1136/annrheumdis-2021-221915.
Khosrow-Khavar, F., Kim, S. C., Lee, H., Lee, S. B., & Desai, R. J. (2022). Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221915
Khosrow-Khavar, Farzin, et al. "Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study." Annals of the rheumatic diseases vol. (2022). doi: https://doi.org/10.1136/annrheumdis-2021-221915
Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022 Jan 13; doi: 10.1136/annrheumdis-2021-221915. Epub 2022 Jan 13. PMID: 35027405.
Copy Download .nbib Format: NLM
Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines.

Archives of medical science : AMS

Batko B, Korkosz M, Juś A, Wiland P.
PMID: 34522257
Arch Med Sci. 2019 Mar 29;17(5):1286-1293. doi: 10.5114/aoms.2019.84092. eCollection 2021.

INTRODUCTION: International recommendations are intended to help rheumatologists in the effective management of rheumatoid arthritis (RA) through an evidence-based approach. This research aimed to evaluate management patterns and associated difficulties encountered by rheumatologists in daily practice.MATERIAL AND METHODS: Interviewers...

Cite
Batko B, Korkosz M, Juś A, et al. Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines. Arch Med Sci. 2019;17(5):1286-1293doi: 10.5114/aoms.2019.84092.
Batko, B., Korkosz, M., Juś, A., & Wiland, P. (2021). Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines. Archives of medical science : AMS, 17(5), 1286-1293. https://doi.org/10.5114/aoms.2019.84092
Batko, Bogdan, et al. "Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines." Archives of medical science : AMS vol. 17,5 (2021): 1286-1293. doi: https://doi.org/10.5114/aoms.2019.84092
Batko B, Korkosz M, Juś A, Wiland P. Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines. Arch Med Sci. 2019 Mar 29;17(5):1286-1293. doi: 10.5114/aoms.2019.84092. eCollection 2021. PMID: 34522257; PMCID: PMC8425259.
Copy Download .nbib Format: NLM
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So .

Annals of the rheumatic diseases

Schulze-Koops H, Specker C, Krueger K.
PMID: 32581084
Ann Rheum Dis. 2020 Jun 24; doi: 10.1136/annrheumdis-2020-218235. Epub 2020 Jun 24.

No abstract available.

Cite
Schulze-Koops H, Specker C, Krueger K. Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218235.
Schulze-Koops, H., Specker, C., & Krueger, K. (2020). Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218235
Schulze-Koops, Hendrik, et al. "Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218235
Schulze-Koops H, Specker C, Krueger K. Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So . Ann Rheum Dis. 2020 Jun 24; doi: 10.1136/annrheumdis-2020-218235. Epub 2020 Jun 24. PMID: 32581084.
Copy Download .nbib Format: NLM
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic .

Annals of the rheumatic diseases

Schulze-Koops H, Krueger K, Specker C.
PMID: 32576567
Ann Rheum Dis. 2020 Jun 23; doi: 10.1136/annrheumdis-2020-218223. Epub 2020 Jun 23.

No abstract available.

Cite
Schulze-Koops H, Krueger K, Specker C. Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218223.
Schulze-Koops, H., Krueger, K., Specker, C. (2020). Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218223
Schulze-Koops, Hendrik, et al. "Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218223
Schulze-Koops H, Krueger K, Specker C. Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic . Ann Rheum Dis. 2020 Jun 23; doi: 10.1136/annrheumdis-2020-218223. Epub 2020 Jun 23. PMID: 32576567.
Copy Download .nbib Format: NLM
Influence of tumor necrosis factor α in rheumatoid arthritis.

GMS health technology assessment

Kulp W, Corzillus M, Greiner W, Pientka L, Siebert U, von der Schulenburg JM, Wasem J.
PMID: 21289933
GMS Health Technol Assess. 2005 Dec 21;1:Doc12.

OBJECTIVE: Rheumatoid arthritis (RA) is the most prevalent inflammatory rheumatic disorder. It is a chronic and incurable disease that leads to painful inflammation, often irreversible joint damage, and eventually to functional loss. Conventional treatment is based on unspecific immunosuppressive...

Cite
Kulp W, Corzillus M, Greiner W, et al. Influence of tumor necrosis factor α in rheumatoid arthritis. GMS Health Technol Assess. 2005;1:Doc12
Kulp, W., Corzillus, M., Greiner, W., Pientka, L., Siebert, U., von der Schulenburg, J. M., & Wasem, J. (2005). Influence of tumor necrosis factor α in rheumatoid arthritis. GMS health technology assessment, 1Doc12.
Kulp, Werner, et al. "Influence of tumor necrosis factor α in rheumatoid arthritis." GMS health technology assessment vol. 1 (2005): Doc12.
Kulp W, Corzillus M, Greiner W, Pientka L, Siebert U, von der Schulenburg JM, Wasem J. Influence of tumor necrosis factor α in rheumatoid arthritis. GMS Health Technol Assess. 2005 Dec 21;1:Doc12. PMID: 21289933; PMCID: PMC3011313.
Copy Download .nbib Format: NLM
A systematic review of infliximab in the treatment of early rheumatoid arthritis.

Therapeutics and clinical risk management

Du Pan SM, Gabay C, Finckh A.
PMID: 18473014
Ther Clin Risk Manag. 2007 Oct;3(5):905-11. doi: 10.2147/tcrm.s988.

BACKGROUND: Several health authorities have recently revised the indication of infliximab (IFX) to include the treatment of early rheumatoid arthritis (RA). The aim of this systematic review of the literature was to appraise the efficacy, safety, and cost-effectiveness of...

Cite
Du Pan SM, Gabay C, Finckh A. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(5):905-11doi: 10.2147/tcrm.s988.
Du Pan, S. M., Gabay, C., & Finckh, A. (2007). A systematic review of infliximab in the treatment of early rheumatoid arthritis. Therapeutics and clinical risk management, 3(5), 905-11. https://doi.org/10.2147/tcrm.s988
Du Pan, Sophie Martin, et al. "A systematic review of infliximab in the treatment of early rheumatoid arthritis." Therapeutics and clinical risk management vol. 3,5 (2007): 905-11. doi: https://doi.org/10.2147/tcrm.s988
Du Pan SM, Gabay C, Finckh A. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag. 2007 Oct;3(5):905-11. doi: 10.2147/tcrm.s988. PMID: 18473014; PMCID: PMC2376089.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 120 entries